Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1325"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_numb_subjects | |
| ?:Evidence_object_dose | |
| ?:Evidence_precip_dose | |
| ?:Evidence_type | |
| ?:Evidence_value | |
| ?:content |
"route of administration: oral
study duration: quetiapine 300 mg bid and haloperidol 7.5 mg bid for 7 consecutive days after titration periods of at least 17 days for quetiapine and two days for haloperidol (see Figure 1). Haloperidol was given after participant's quetiapine levels were considered to have reached steady state (see NOTE below)
population: 12 adults with schizophrenic, schizoaffective, or bipolar disorder; 11 male, 1 female
tested for known CYP450 polymorphisms? No
ages: 18 - 60
description:
Although co-administration of haloperidol led to an
increase in mean plasma quetiapine concentration (Figure 2A) and a decrease in Cl/f (10%), the changes
were small and not clinically significant (Table 2). The same was true for increases in geometric means for AUCtSS, CmaxSS, and CminSS (11%, 23%, and 17%, respectively). The trend toward increased AUCtSS etween days 17B and 5B was seen for 9 of 12 patients. The increases in CmaxSS and CminSS were considered to be of no clinical concern.
NOTE: during co-administration of haloperidol six patients recieved benztropine mesylate"
|
| dc:creator | |
| dc:date |
"09/22/2009 19:11:15"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ haloperidol_increases_auc_quetiapine, <http://purl.org/swan/1.2/swan-commons#citesAsRefutingEvidence>, evidence_1591 }